The section entitled “Treg-based therapies in cancer” emphasizes two critical aspects of TI(tumor-infiltrating)-Tregs that, when perturbed, can modify their function: (i) their highly activated phenotype via stimulatory cell surface receptors; and (ii) their metabolic status. The gene discussed is CD177; the disease is neoplasm.